Related Tags >> Provenge Prostate Cancer Cancer Drugs FDA

Dendreon News

Most Popular Dendreon Story

Is Dendreon a likely takeover target?

April 30, 2009 — 10:41am ET | By John Carroll

The stock analysts like everything they've seen about Dendreon's new data on the prostate cancer vaccine Provenge. They like it so much, some think the biotech has made itself an appealing buyout... Read more...

Dendreon Press Releases

Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
PRESS RELEASE: Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge For Prostate Cancer

Latest Headlines

Dendreon CEO predicts an FDA approval for cancer vax
May 13, 2009
Is Dendreon a likely takeover target?
April 30, 2009
Dendreon shares bounce on late-stage Provenge data
April 29, 2009
Dendreon beefs up pipeline work with oral cancer drug
April 21, 2009
Dendreon reveals Provenge data at AARC meeting
April 20, 2009
Analysts scamper to catch up to Provenge news
April 17, 2009
Dendreon says Provenge trial a success
April 14, 2009
Dendreon shares soar on Provenge survival data
October 6, 2008
GVAX questions depress Dendreon shares
August 28, 2008
Next Provenge milestone: interim data
August 13, 2008
Optimistic Dendreon revs up second program
April 16, 2008
ALSO NOTED: Dendreon shares jump on investment deal; Iomai in pact with Merck; Foundation antes millions for MS leads; and much
April 3, 2008
SPOTLIGHT: FDA accelerates Provenge timeline
March 12, 2008
House committee decides against Provenge hearings
February 14, 2008
FDA's stand on Provenge riles cancer patients
January 3, 2008
Pharmacyclics CEO takes aim at FDA decision-making
January 3, 2008
Congressmen want closer look at Provenge delay
December 14, 2007
Is the fast track system a sham?
December 3, 2007
SPOTLIGHT: Enrollment wrapped on Provenge Phase III
October 23, 2007
SPOTLIGHT: Dendreon faces probe
July 11, 2007

Paid Research Reports

More Research Reports >>